AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Investor Day (May 2019)

56 slides from AMAG Pharmaceuticals's investor day presentation, May 22, 2019

  1. Slide 1: Analyst Day May 22, 2019

    Analyst Day May 22, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Linda Lennox, Vice President, Investor Relations

    Linda Lennox Vice President, Investor Relations 2

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, stat

  4. Slide 4: Cautionary Disclosure Regarding AMAG's Long-Term Outlook

    Cautionary Disclosure Regard AMAG’s Long-Term Outlook Slides 7, 9, 18, 41, 45-48, 51, 52 and 54 contain forward-looking estimates of AMAG’s growth trajectory in revenue and adjusted EBITDA on a multi- year timeframe based on a strategy of maximizing commercial product opportunities to fund investmen

  5. Slide 5: Agenda for the Day

    Agenda for the Day Welcome Linda Lennox, AMAG Vice President, Investor Relations Strategic overview and outlook Bill Heiden, AMAG President and Chief Executive Officer AMAG-423 • Disease overview John Barton, MD, OB/GYN, MFM Specialist, Baptist Health, KY* • MOA, Phase 2a data, current Phase 2b/3a t

  6. Slide 6: Strategic Overview and Outlook

    Strategic Overview and Outlook Bill Heiden AMAG President and CEO 6

  7. Slide 7: Key Take-Aways for Today

    Key Take-Aways for Today View to 2022 is bright Valuable product • Current commercial products portfolio today will continue to perform well • Development-stage products Significant progress • Commercial products growing represent new & durable from 2017 to today • Development-stage products revenue

  8. Slide 8: Agenda: Strategic Overview

    Agenda Strategic Overview Progress to Date Portfolio Value © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 8

  9. Slide 9: Overview: 2017-2022 Strategic Plan

    Overview: 2017-2022 Strategic Plan Delivering Innovative Therapies Investing Innovation Expanding Creating new, durable revenue streams and capabilities and Acquiring/licensing profitable growth investing in the development-stage development products to address and launch of new unmet medical produc

  10. Slide 10: Agenda: Progress to Date

    Agenda Strategic Overview Progress to Date Portfolio Value © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 10

  11. Slide 11: Strong Progress To Date On Strategic Evolution: 2017

    Strong Progress To Date On Strategic Evolution 2017-2022 Maximizing Commercial Product Opportunities and Adding New Products to the Portfolio 2017 Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia CKD Broad label all iron deficiency anemia HEMATOLOGY Tr

  12. Slide 12: Strong Progress on Strategic Evolution: 2018

    Strong Progress on Strategic Evolution 2017-2022 Maximizing Commercial Product Opportunities and Adding New Products to the Portfolio 2018 Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia CKD Broad label all iron deficiency anemia HEMATOLOGY Treatment

  13. Slide 13: Strong Progress on Strategic Evolution: 2018 Additions

    Strong Progress on Strategic Evolution 2017-2022 Maximizing Commercial Product Opportunities and Adding New Products to the Portfolio 2018 Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia CKD Broad label all iron deficiency anemia Anticoagulant reversa

  14. Slide 14: Historical Value Drivers Fund Future Value Drivers

    Strong Progress on Strategic Evolution 2017-2022 Historical Value Drivers Fund Future Value Drivers AMAG-423 ciraparantag Fundingfunding HISTORICAL Value of AMAG FUTURE Value of AMAG © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 14

  15. Slide 15: AMAG: Diversified Product Portfolio Leveraging Two Commercial Platforms

    AMAG: Diversified Product Portfolio Leveraging Two Strong Commercial Platforms Coming Soon ciraparantag AMAG-423 Commercial Hematology Women’s Health Maternal Health 48 Sales Representatives => 124 Sales Representatives => OB/GYNS Heme Clinics & Hospitals STRONG COMMERCIAL PLATFORM © 2019 AMAG Pharm

  16. Slide 16: AMAG Product Development Milestone Calendar

    AMAG Product Development Milestone Calendar 1H-2019 2H-2019 1H-2020 2H-2020 1H-2021 2H-2021 June 23 Potential PDUFA date commercial Vyleesi launch 423 - Target complete enrollment in Phase 2b/3a trial Topline data NDA submission Potential FDA approval AMAG Closed End of Phase 2 Complete NDA Potentia

  17. Slide 17: Agenda: Portfolio Value

    Agenda Strategic Overview Progress to Date Portfolio Value © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 17

  18. Slide 18: Unmet Medical Needs Representing Significant Commercial Opportunities

    Unmet Medical Needs Representing Significant Commercial Opportunities Net Revenues Per Year For Every 1% of Market Penetration? AMAG-423 ciraparantag Affects 5.8 million U.S. premenopausal women1 ~6 million patients on NOAC / LMWH therapy1 Annual U.S. incidence of preeclampsia: (1 in 10 premenopausa

  19. Slide 19: Tony Casciano, Chief Commercial Officer

    Tony Casciano AMAG Chief Commercial Officer 19

  20. Slide 20: AMAG-423 Has the Potential to Address a Serious Unmet Need

    AMAG-423 Has the Potential to Address a Serious Unmet Need Significant burden to the healthcare system  Unmet medical need Annual U.S. incidence of Annual U.S. incidence of preeclampsia SEVERE preeclampsia  Strong target product profile ~140,000 ~50,000  Space for innovation pregnant women pregna

  21. Slide 21: Vyleesi (bremelanotide) Commercial Overview

    TM TMaa Vyleesi (bremelanotide) Commercial Overview Meghan Rivera Vice President, Head of Women’s Health Sales and Marketing Vyleesi is an investigational product currently under review by FD. Safety and efficacy has not been established 21

  22. Slide 22: Situation

    Situation When it comes to female sexual health–and more specifically hypoactive sexual desire disorder (HSDD)–there’s a huge gap in the market. 22

  23. Slide 23: The HSDD Market Provides Substantial Untapped Opportunity: 1 in 10

    The HSDD Market Provides Substantial Untapped Opportunity — 1/101,2 — Number of pre- menopausal women who have low desire with associated distress 1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol.

  24. Slide 24: The HSDD Market Provides Substantial Untapped Opportunity: 95%

    The HSDD Market Provides Substantial Untapped Opportunity — 95%1 — Percentage of women who are not yet aware of HSDD and that their distressing lack of desire is a medical condition 1. Palatin supported research that was performed by Burke, Inc., an ISO 20252–certified company, in compliance with th

  25. Slide 25: The HSDD Market Provides Substantial Untapped Opportunity: 91%

    The HSDD Market Provides Substantial Untapped Opportunity — 91%1 — Percentage of HCPs not satisfied with current treatment options 1. Palatin supported research that was performed by Burke, Inc., an ISO 20252–certified company, in compliance with the established standard 25 for market, opinion, and

  26. Slide 26: Question and Answer on Treatment Awareness

    Question How can women seek treatment for a condition that they don’t even know about? Answer AMAG will make HSDD part of the larger cultural conversation and connect with mass audiences. 26

  27. Slide 27: Can it be Done?

    Can it be Done?? Following the launch of a novel solution for depression, the rate of diagnosis, dialogue and understanging about the condition dramatically shifted. Similarly, with the introduction of Vyleesi, the landscape for the treatment of female sexual dysfunction will change fundamentally. 2

  28. Slide 28: The "How"

    The “How” 28

  29. Slide 29: An Approach with Proven Results

    An Approach with Proven Results Several health and wellness brands have embraced consumer branding principles and prioritized digital channels as growth engines, showing tremendous success. 29

  30. Slide 30: A Focus on Digital Channels

    A Focus on Digital Channels Focus paid media on social and digital channels where women already are. 30

  31. Slide 31: Destigmatizing the Conversation

    Destigmatizing the Conversation Create an online community where women with HSDD can get a wealth of accurate resources, check their symptoms, and get support. 31

  32. Slide 32: Accelerating Path to Treatment

    Accelerating Path to Treatment Create a line-up experience program to allow early adopters to get an advanced prescription through telemedicine. 32

  33. Slide 33: Ensuring Provider Readiness

    Ensuring Provider Readiness Activate a sales force and HCP campaign that will ensure our grant rate allows us to capitalize on consumer interest. 33

  34. Slide 34: The Initial Metrics Speak for Themselves

    The Initial Metrics Speak for Themselves Leading indicators of campaign performance continue to instill our confidence in our approach… - Close to 50% open rate on email to providers, more than double industry benchmark - In just week one, 2.82M impressions, 80k clicks to our community, and over 700

  35. Slide 35: Experience, Experience, Experience

    Experience, Experience, Experience Vyleesi is all about experience. From the experience of engaging with our brand to the meaningful impact we believe Vyleesi will have on women’s lives. And this gives us reason to believe that the experience will reverberate via word of mouth and earned media 35

  36. Slide 36: In Summary

    In Summary • There is a significant market opportunity and unmet need • The Vyleesi experience will allow for reverberation and growth • A disruptive go-to-market strategy is critical to drive awareness and rapid uptake 36

  37. Slide 37: Tony Casciano, Chief Commercial Officer

    Tony Casciano AMAG Chief Commercial Officer 37

  38. Slide 38: Ciraparantag Has the Potential to Address a Serious Unmet Medical Need

    Ciraparantag Has the Potential to Addresses a Serious Unmet Medical Need Significant cost associated with life-threatening bleeds Estimated NOAC/LMWH Patients on patients per year  Unmet medical need requiring a reversal agent NOAC/LMWH  Strong target product profile ~6 million ~150,000 Xarelto®,

  39. Slide 39: Ted Myles, Chief Financial Officer

    Ted Myles Chief Financial Officer

  40. Slide 40: Agenda: Financial Evolution, Business Development

    Agenda Financial Evolution Business Development © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 40

  41. Slide 41: Overview: 2017-2022 Strategic Plan

    Overview: 2017-2022 Strategic Plan Delivering Innovative Therapies Investing Innovation Expanding Creating new, durable revenue streams and capabilities and Acquiring/licensing profitable growth investing in the development-stage development products to address and launch of new unmet medical produc

  42. Slide 42: 2016: Prior to the Business Evolution AMAG was Heavily Leveraged

    2016 | Prior to the Business Evolution AMAG was Heavily Leveraged More than $1B in Debt, Near-Term Maturities and Restrictive Covenants Capital Structure Key Items 12/31/16 Cash: $578M Outstanding debt balance: $1,028M Total annual interest cost: $60M Debt Payments $M $500 $218 $258 $18 $18 $18 2017

  43. Slide 43: 2017: Debt Reduction and Maturity Extensions

    2017 | Debt Reduction and Maturity Extensions Removed Term Loan and Extended Time to Maturity to Support New Product Launches Capital Structure Key Items 12/31/16 6/30/17 Cash: $578M $399M Outstanding debt balance: $1,028M $861M Total annual interest cost: $60M $51M Debt Payments $M $500 $320 $41 20

  44. Slide 44: 2019: Balance Sheet Evolved, Significantly De-levered

    2019 | Balance Sheet Evolved, Significantly De-levered and Extended Maturity Current capital structure supports development of innovative products Capital Structure Key Items 12/31/16 6/30/17 3/31/19 Cash: $578M $399M $267M Outstanding debt balance: $1,028M $861M $320M Total annual interest cost: $6

  45. Slide 45: Maximize Commercial Product Opportunities to Fund Investments in New Products

    Maximize Commercial Product Opportunities to Fund Investments in New Products Revenues $1,000 (Millions) $500 $0 2018 2019 2020 2021 2022 Current Commercial Portfolio © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 45

  46. Slide 46: Commercial Product Portfolio Expectations 2019-2022

    Commercial Product Portfolio Expectations 2019-2022 • Continued growth through market expansion and increasing market share − Brand on track to achieve >$200M annual revenues • Continue to promote benefits of Makena subcutaneous auto-injector − 1Q19: SC auto-injector 54% market share of HPC market •

  47. Slide 47: Strategic Evolution: New Products Drive Future Growth

    Strategic Evolution: New Products Drive Future Growth Current Commercial Products Provide Stable Cash Flows and Growth Potential Revenues $1,000 (Millions) $500 $0 2018 2019 2020 2021 2022 Current Commercial Portfolio © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 47

  48. Slide 48: Strategic Evolution: Projected U.S. Revenues and Adjusted EBITDA

    Strategic Evolution: New Products Drive Future Growth Current Commercial Products Provide Stable Cash Flows Projected U.S. Revenues $1,000 (Millions) Potential AMAG-423 ciraparantag $500 $0 2018 2019 2020 2021 2022 Current Commercial Portfolio Current Development Portfolio Adjusted EBITDA © 2019 AMA

  49. Slide 49: Agenda: AMAG Evolution, Business Development

    Agenda AMAG Evolution Business Development © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 49

  50. Slide 50: Future Portfolio Building: Search and Evaluation Criteria

    Future Portfolio Building: Search and Evaluation Criteria . Core therapeutic areas (TAs) (maternal health, Therapeutic hem/onc & select hospital) Criteria . Adjacent TAs (women’s health, nephrology) . Differentiated & durable Financial . Criteria Stage of development . Cash payback period and IRR Le

  51. Slide 51: Acquisition of Ciraparantag and AMAG-423 Provide Global Opportunities

    Acquisition of Ciraparantag and AMAG-423 Provide Global Opportunities • Acquisition of ciraparantag and AMAG-423 provide AMAG with global opportunities • Opportunity for ex-U.S. out-licensing . Potential source of non-dilutive capital . Initiation of ex-U.S. development © 2019 AMAG Pharmaceuticals,

  52. Slide 52: In Summary

    In Summary • Transformation of balance sheet to support evolution of business plan • Short lived EBITDA-negative phase in 2019, return to EBITDA neutral in 2020 as pipeline matures and newer products begin to contribute cash flows • Recent pipeline additions provide global opportunities © 2019 AMAG

  53. Slide 53: Bill Heiden, Closing Remarks

    Bill Heiden Closing Remarks 53

  54. Slide 54: Key Take-Aways for Today

    Key Take-Aways for Today View to 2022 is bright Valuable product • Current commercial products portfolio today will continue to perform well • Development-stage products Significant progress • Commercial products growing represent new & durable from 2017 to today • Development-stage products revenue

  55. Slide 55: 2019 Development Goals

    2019 Development Goals Commercial Products Continue to Fund Investments in Valuable Pipeline Products Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia CKD Broad label all iron deficiency anemia Anticoagulant reversal agent Ciraparantag (potential for o

  56. Slide 56: Thank you for coming!

    Thank you for coming! AMAG Analyst Day May 22, 2019 © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 56

AMAG Pharmaceuticals — Investor Day (May 2019) on 6ix